Peer-reviewed veterinary case report
Cat with soft tissue sarcoma treated with doxorubicin chemotherapy
By Torrigiani, Filippo et al.·Published in Journal of Feline Medicine and Surgery Open Reports·2019·Centro Specialistico Veterinario (Specialist Veterinary Centre), Milan, Italy, Italy·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Neoadjuvant and adjuvant doxorubicin chemotherapy in a case of feline soft tissue sarcoma
- Species:
- cat
Plain-English summary
A 7-year-old male neutered domestic shorthair cat was brought to the vet with a slow-growing mass on his face that had been present for two months. After a CT scan and biopsy, the mass was identified as a soft tissue sarcoma. The cat received neoadjuvant chemotherapy with doxorubicin, which helped shrink the tumor before surgery. Following the surgical removal of the tumor, he continued with more doxorubicin treatments, but unfortunately, the tumor came back about 259 days later.
People also search for: cat soft tissue sarcoma treatment · doxorubicin for cats · cat tumor recurrence signs
Abstract
Case summary A 7-year old male neutered domestic shorthair cat was presented with a 2 month history of a slow-growing mass on the right zygomatic area. A CT scan revealed a soft tissue mass in the right zygomatic region with no alterations of the underlying bone and features of local invasiveness. Cytology was suggestive of a mesenchymal tumour and histopathology from an incisional biopsy was consistent with a soft tissue sarcoma (STS). The cat was treated with neoadjuvant intravenous doxorubicin chemotherapy at a dose of 25 mg/m 2 , every two weeks. The patient experienced a partial response and underwent surgical excision of the tumour. Doxorubicin was continued as an adjuvant treatment for three further chemotherapy sessions, at a dose of 25 mg/m 2 every 21 days. Local tumour recurrence was detected on clinical examination and cytologically confirmed 259 days following surgery. Relevance and novel information Treatment with neoadjuvant doxorubicin can be considered in cases of inoperable STSs in order to cytoreduce the tumour and improve the chances of achieving complete surgical margins. The role of adjuvant chemotherapy in this setting remains unclear.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1177/2055116919857870